

## Alcohol Addiction Therapeutic Pipeline Market Review, H2 2016

Alcohol Addiction Treatment Pipeline Review H2 2016

PUNE, INDIA, October 21, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report



provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

Get Sample Report @ <a href="https://www.wiseguyreports.com/sample-request/619293-alcohol-addiction-pipeline-review-h2-2016">https://www.wiseguyreports.com/sample-request/619293-alcohol-addiction-pipeline-review-h2-2016</a>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and

## minor projects

- The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcohol Addiction

## Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Alcohol Addiction Overview 10

Therapeutics Development 11

Pipeline Products for Alcohol Addiction - Overview 11

Pipeline Products for Alcohol Addiction - Comparative Analysis 12

Alcohol Addiction - Therapeutics under Development by Companies 13

Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes 15

Alcohol Addiction - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Alcohol Addiction - Products under Development by Companies 19

Alcohol Addiction - Products under Investigation by Universities/Institutes 21

Alcohol Addiction - Companies Involved in Therapeutics Development 22

AbbVie Inc. 22

Addex Therapeutics Ltd 23

Adial Pharmaceuticals, LLC 24

Astraea Therapeutics, LLC 25

AstraZeneca Plc 26

Bionex Pharmaceuticals LLC 27

Bioprojet SCR 28

Cerecor Inc. 29

Curemark, LLC 30

Eli Lilly and Company 31
Ethypharm S.A. 32
Euthymics Bioscience, Inc. 33
H. Lundbeck A/S 34
Heptares Therapeutics Limited 35
Indivior Plc 36
Johnson & Johnson 37
Kinnov Therapeutics SAS 38
Kyorin Pharmaceutical Co., Ltd. 39
Lohocla Research Corporation 40
Omeros Corporation 41
Pfizer Inc. 42
SK Biopharmaceuticals Co., Ltd. 43
Tonix Pharmaceuticals Holding Corp. 44

Access Report @ <a href="https://www.wiseguyreports.com/reports/619293-alcohol-addiction-pipeline-review-h2-2016">https://www.wiseguyreports.com/reports/619293-alcohol-addiction-pipeline-review-h2-2016</a>

Get in touch:

LinkedIn: <a href="https://twitter.com/company/4828928">www.linkedin.com/company/4828928</a>
Twitter: <a href="https://twitter.com/WiseGuyReports">https://twitter.com/WiseGuyReports</a>

Facebook: <a href="https://www.facebook.com/Wisequyreports-1009007869213183/?fref=ts">https://www.facebook.com/Wisequyreports-1009007869213183/?fref=ts</a>

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.